Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy (PSP)

Related Pages

[4R Tauopathies](/diseases/4r-tauopathies-genetics) | [Alzheimer's Disease](/diseases/alzheimers-disease) | [Parkinson's Disease](/diseases/parkinsons-disease) | [Corticobasal Degeneration](/diseases/corticobasal-degeneration) | [Multiple System Atrophy](/diseases/multiple-system-atrophy) | [Tau Protein](/proteins/tau) | [MAPT Gene](/genes/mapt) | [Neuroinflammation](/mechanisms/neuroinflammation) | [Oxidative Stress](/mechanisms/oxidative-stress-pathway) | [Substantia Nigra](/cell-types/substantia-nigra-dopamine-neurons) | [Microglia](/cell-types/microglia) | [Astrocytes](/cell-types/astrocytes) | [Globus Pallidus](/cell-types/globus-pallidus) | [Iron Metabolism](/mechanisms/iron-metabolism-neurodegeneration) | [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-in-neurodegeneration) | [Autophagy Dysfunction](/mechanisms/autophagy-lysosomal-pathway) | [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)

Introduction

Progressive Supranuclear Palsy (PSP)

Related Pages

[4R Tauopathies](/diseases/4r-tauopathies-genetics) | [Alzheimer's Disease](/diseases/alzheimers-disease) | [Parkinson's Disease](/diseases/parkinsons-disease) | [Corticobasal Degeneration](/diseases/corticobasal-degeneration) | [Multiple System Atrophy](/diseases/multiple-system-atrophy) | [Tau Protein](/proteins/tau) | [MAPT Gene](/genes/mapt) | [Neuroinflammation](/mechanisms/neuroinflammation) | [Oxidative Stress](/mechanisms/oxidative-stress-pathway) | [Substantia Nigra](/cell-types/substantia-nigra-dopamine-neurons) | [Microglia](/cell-types/microglia) | [Astrocytes](/cell-types/astrocytes) | [Globus Pallidus](/cell-types/globus-pallidus) | [Iron Metabolism](/mechanisms/iron-metabolism-neurodegeneration) | [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-in-neurodegeneration) | [Autophagy Dysfunction](/mechanisms/autophagy-lysosomal-pathway) | [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)

Introduction

Progressive Supranuclear Palsy (PSP), also known as Steele-Richardson-Olszewski syndrome, is a progressive neurodegenerative disorder characterized by vertical gaze palsy, postural instability, [parkinsonism](/diseases/parkinsons-disease), and frontal cognitive dysfunction[@braincomputer2023] PMID: 40465013. PSP is classified as a [4R tauopathy](/mechanisms/4r-tauopathy-mechanisms), meaning it is associated with the abnormal accumulation of the microtubule-associated protein [tau](/proteins/tau) in the brain[@neural2024].

PSP is now recognized as part of a spectrum of disorders with overlapping clinical and pathological features, collectively termed "PSP-spectrum disorders." These include classic PSP (Richardson syndrome), as well as variant phenotypes such as PSP-parkinsonism (PSP-P), PSP-pure akinesia with gait freezing (PSP-PAGF), and cortical syndromes such as PSP with predominant cerebellar ataxia (PSP-C) and PSP with predominant frontal presentation (PSP-F) PMID: 32487421.

Overview

Progressive Supranuclear Palsy (PSP) is a [4R tauopathy](/mechanisms/4r-tauopathy-mechanisms) characterized by the accumulation of [tau protein](/proteins/tau) in the brainstem, [basal ganglia](/brain-regions/basal-ganglia), and cerebellar structures PMID: 37381926. Key features include vertical gaze palsy, postural instability, and progressive akinesia. PSP is caused by tau protein dysfunction and aggregation, with the [MAPT](/genes/mapt) H1 haplotype as the primary genetic risk factor. The disease typically presents in the sixth decade and progresses rapidly, with a median survival of 7-9 years.

Key Pathological Features:

• 4R tau accumulation in neurons and glia
• Neurofibrillary tangles in brainstem nuclei
• Tufted astrocytes
• Globose neurofibrillary degeneration

• Vertical supranuclear gaze palsy (diagnostic hallmark)
• Postural instability with falls
• Progressive akinesia and rigidity
• Frontal cognitive dysfunction

Epidemiology and Risk Factors

Prevalence and Incidence

PSP is a rare but not uncommon neurodegenerative disorder:

• Estimated prevalence: 5-6 per 100,000 individuals[^3]
• Incidence: Approximately 1-2 per 100,000 person-years
• Age of onset: Typically 60-65 years (range 40-80 years)
• Slight male predominance (1.5:1 male-to-female ratio)
• No clear ethnic or geographic clustering

Genetic Risk Factors

The MAPT gene on chromosome 17q21.31 represents the strongest genetic risk factor for PSP. The H1 haplotype confers an odds ratio of approximately 5.5-8.0 for PSP risk[^4]. Additional risk loci identified through GWAS include:

• MOBP (OR 1.25): Myelin-associated oligodendrocyte basic protein[^5]
• STX6 (OR 1.29): Syntaxin-6, involved in autophagy
• EIF2AK3 (OR 1.23): Endoplasmic reticulum stress response[^5]
• SLCO1A2 (OR 1.22): Organic anion transporter
• DUSP10 (OR 1.18): MAPK phosphatase
• TRIM11 (OR 1.15): Ubiquitin ligase

Environmental Risk Factors

Environmental exposures may contribute to PSP risk through mechanisms including mitochondrial dysfunction, oxidative stress, and neuroinflammation. See Environmental Risk Factors in Progressive Supranuclear Palsy for a detailed synthesis of epidemiological evidence.

Pathophysiology

4R Tau Pathology

PSP is characterized by the predominant accumulation of 4-repeat (4R) tau isoforms in neurofibrillary tangles and glial inclusions[^6]. Unlike Alzheimer's Disease, where both 3R and 4R tau are present, PSP shows a selective increase in 4R tau due to dysregulated exon 10 splicing in the MAPT gene.

The tau pathology in PSP exhibits distinct patterns:

• Globose neurofibrillary tangles: Located in subcortical nuclei including the Subthalamic Nucleus (STN), Globus Pallidus (GP), substantia nigra (SN), and brainstem raphe nuclei[^7]
• Tufted astrocytes: Astrocytic inclusions specific to PSP, arranged in tufts around the nucleus
• Coiled bodies: Oligodendroglial inclusions in the white matter
• Thread-like processes: Tau-positive neurites in the neuropil

Tau Isoform Biology

The MAPT gene contains 16 exons, with alternative splicing producing six tau isoforms in the human brain. Exon 10 encodes one of the microtubule-binding repeats, and its inclusion produces 4R tau isoforms while exclusion produces 3R isoforms. In normal adult brain, the 3R:4R ratio is approximately 1:1. In PSP, the ratio shifts dramatically toward 4R (approximately 3:1 or higher)[^8].

The mechanisms underlying this shift include:

• Mutations in the MAPT splice donor site of exon 10
• Alterations in splicing factor expression (SFRS1, HNRNPA1, HNRNPA2B1)
• Epigenetic modifications to the MAPT promoter region
• H1 haplotype-specific expression differences

Cryo-EM Tau Filament Structures

Recent cryo-electron microscopy studies have revealed distinct tau filament folds in different tauopathies[^9]:

• PSP-tau filament: C-shaped, three-layered assembly distinct from AD and CBD
• CBD-tau filament: Distinct double-C-shaped structure
• AD-tau filament: Paired helical filament (PHF) and straight filament (SF)

Selective Circuit Vulnerability

PSP demonstrates remarkable selectivity for specific neural circuits:

Oculomotor Circuit Disruption

The supranuclear ophthalmoplegia in PSP results from degeneration of key structures:

• Rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF): Controls vertical saccades
• Interstitial nucleus of Cajal (INC): Involved in vertical gaze holding
• Superior colliculus: Visuomotor integration for eye movements
• Pontine omnipause neurons: Gate horizontal saccades

Midbrain Atrophy

The "hummingbird sign" on MRI reflects midbrain atrophy with relative preservation of the pons, creating a characteristic appearance on sagittal images[^11]. The midbrain tegmentum shows prominent atrophy with dilation of the cerebral aqueduct.

The "penguin sign" or "king penguin sign" on axial images reflects:

• Midbrain atrophy with preservation of pontine volume
• Dilated third ventricle
• Atrophied cerebral peduncles

Basal Ganglia Degeneration

The Basal Ganglia circuits are heavily affected:

• Subthalamic nucleus (STN): Critical for motor inhibition, degeneration contributes to falls
• Globus pallidus internus (GPi): Output nucleus showing neurofibrillary tangles
• Substantia nigra pars compacta (SNc): Dopaminergic neuron loss contributes to parkinsonism

Neuroinflammation

Microglial Activation

TSPO-PET studies demonstrate widespread Microglia activation in PSP[^12]:

• Highest activation in the basal ganglia, Brainstem, and frontal cortex
• Correlates with disease severity and progression
• Precedes detectable neurodegeneration in some regions

Astrocytes

• Reactive astrocytes in affected regions
• Tau-positive astrocytes (tufted astrocytes) are pathognomonic
• May contribute to disease progression through inflammatory mediators

Cytokine and Chemokine Profiles

Elevated levels of inflammatory markers in PSP:

• IL-6 (interleukin-6): Pro-inflammatory cytokine
• TNF-α (tumor necrosis factor-alpha): Key mediator of neuroinflammation
• IL-1β (interleukin-1 beta): Associated with tau pathology
• CCL2 (MCP-1): Monocyte chemoattractant

Complement System Activation

The complement system is activated in PSP:

• C1q deposition on neurons and glia
• C3d and C4d in affected brain regions
• May contribute to synaptic loss and neuronal death

Neurotransmitter Deficits

Dopaminergic Loss

PSP shows prominent dopaminergic dysfunction[^13]:

• 50-70% reduction in Striatum Dopamine terminals
• Loss of SNc neurons, particularly in the ventrolateral tier
• Fewer Lewy bodies than Parkinson's disease
• Poor Levodopa response distinguishes PSP from [Parkinson's Disease](/diseases/parkinsons-disease)

• More uniform loss across striatum (vs. posterior-to-anterior gradient in PD)
• Less severe loss than PD despite similar clinical parkinsonism
• Contributes to bradykinesia and rigidity but not tremor

Cholinergic Deficits

Cholinergic dysfunction contributes to cognitive and gait impairment[^14]:

• Pedunculopontine nucleus (PPN): Degeneration contributes to gait freezing and falls
• Laterodorsal tegmental nucleus (LDT): Cholinergic cell loss
• Cortical cholinergic deficits correlate with cognitive impairment

GABAergic and Serotonergic Changes

• Reduced GABA in the basal ganglia contributes to rigidity
• Serotonin raphe nuclei show neurofibrillary tangles
• These deficits may underlie behavioral and mood changes

Myelin and Oligodendrocyte Dysfunction

White matter pathology is a prominent feature of PSP, driven by both primary oligodendrocyte degeneration and secondary effects from axonal loss. The myelin sheath, produced by oligodendrocytes in the CNS, is critical for rapid saltatory conduction and metabolic support of axons. Disruption of this system contributes significantly to clinical progression.

Oligodendrocyte Pathology

Oligodendrocytes are specifically vulnerable in PSP and other 4R tauopathies:

• Coiled bodies: The hallmark tau inclusions in oligodendrocytes appear as curved or irregular cytoplasmic inclusions composed of hyperphosphorylated tau filaments. These are highly characteristic of PSP and help distinguish it from other neurodegenerative diseases[^20].
• Tau aggregation in oligodendrocytes: Oligodendrocytes accumulate 4R tau aggregates that disrupt their normal functions in myelin production and axonal support. The tau pathology in oligodendrocytes precedes significant demyelination in many cases[^21].
• Oligodendrocyte precursor cell (OPC) dysfunction: OPCs fail to differentiate and remyelinate damaged axons in PSP. Studies show reduced OPC proliferation and differentiation capacity in tauopathies[^22].
• MOBP involvement: The myelin-associated oligodendrocyte basic protein (MOBP) gene is a genetic risk factor for PSP, with an odds ratio of approximately 1.25. MOBP variants may affect myelin integrity and tau pathology propagation along white matter tracts[^23].

White Matter Hyperintensities

MRI imaging reveals extensive white matter abnormalities in PSP:

• T2/FLAIR hyperintensities: Confluent white matter hyperintensities are common in PSP, particularly in the frontal lobes and periventricular regions[^24].
• Superior cerebellar peduncle (SCP): The "Hummingbird sign" on MRI reflects midbrain atrophy, but DTI shows that the SCP specifically shows the most prominent fractional anisotropy reduction—a characteristic finding in PSP[^25].
• Diffusion tensor imaging (DTI): PSP shows widespread white matter damage with FA reduction and MD increase in the SCP, corticospinal tracts, corpus callosum, and frontal white matter[^26].
• Progression correlation: White matter hyperintensity burden correlates with clinical progression, particularly gait impairment and executive dysfunction[^27].

Myelin Basic Protein (MBP)

MBP is a major structural protein of the CNS myelin sheath:

• MBP alterations in PSP: Studies show decreased MBP expression in affected white matter regions, reflecting demyelination. CSF MBP levels are elevated in PSP compared to controls[^28].
• MBP as a biomarker: Cerebrospinal fluid MBP reflects active demyelination and correlates with disease severity in PSP[^29].
• Tau-MBP interaction: Pathological tau may directly interfere with MBP trafficking and myelin maintenance in oligodendrocytes[^30].

Proteolipid Protein (PLP)

PLP is the most abundant protein in CNS myelin:

• PLP expression changes: Oligodendrocytes in PSP show altered PLP gene expression, contributing to unstable myelin maintenance[^31].
• PLP and axonal support: Loss of PLP function compromises oligodendrocyte-axonal metabolic coupling, accelerating axonal degeneration[^32].

Remyelination Strategies

Several therapeutic approaches are being investigated for PSP:

• OPC activation: Agents promoting OPC proliferation and differentiation are under investigation for tauopathies[^33].
• Tau reduction in oligodendrocytes: Reducing tau aggregation specifically in oligodendrocytes through antisense oligonucleotides could preserve their function[^34].
• Myelin protective strategies: Agents that stabilize myelin and prevent oligodendrocyte death represent therapeutic approaches[^35].
• Growth factor support: Delivery of neurotrophic factors to support oligodendrocyte survival is being explored[^36].

Contribution to Disease Progression

Myelin and oligodendrocyte dysfunction contributes to PSP progression through multiple mechanisms:

• Conduction deficits: Demyelination slows axonal signal transmission, contributing to motor and cognitive deficits.
• Axonal degeneration: Loss of oligodendrocyte metabolic support leads to secondary axonal degeneration.
• Network disconnection: Damage to the SCP and frontal white matter disrupts critical brain networks, amplifying gait impairment and executive dysfunction.
• Clinical correlation: White matter burden on MRI predicts faster progression, particularly for axial symptoms (gait, balance, falls)[^37].

71. VEGF and Angiogenic Signaling in Tauopathy

The neurovascular unit (NVU) — comprising endothelial cells, pericytes, astrocytes, and neurons — plays a critical role in maintaining cerebral homeostasis. Growing evidence implicates vascular dysfunction and angiogenic signaling abnormalities in the pathogenesis of PSP and related tauopathies.

71.1 VEGF Biology and Signaling Pathways

Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis, vascular permeability, and neurovascular coupling[@vegf2022]. In the brain, VEGF exerts both beneficial (neuroprotective, angiogenic) and potentially harmful (vascular leakage, inflammatory) effects depending on context.

VEGF-A Isoforms

VEGF-A exists in multiple isoforms with distinct biological properties:

• VEGF-A165: The most prevalent isoform, balancing angiogenic and neuroprotective effects
• VEGF-A189: More heparin-binding, with longer tissue retention
• VEGF-A121: More freely diffusible

VEGF Receptor Signaling

VEGF signals through two primary receptor tyrosine kinases:

• VEGFR1 (Flt-1): High affinity for VEGF, modulates vascular development and inflammatory responses
• VEGFR2 (KDR/Flk-1): Primary mediator of angiogenesis and vascular permeability

71.2 Neurovascular Unit Dysfunction in PSP

Blood-Brain Barrier Alterations

Evidence for BBB dysfunction in PSP includes:

• Increased permeability: Post-mortem studies show altered tight junction proteins (claudin-5, occludin) in PSP brains[@bloodbrain2021]
• Pericyte loss: Reduced pericyte coverage correlates with vascular leakage and neuronal dysfunction
• CSF/serum albumin ratio: Elevated in some PSP patients, suggesting BBB compromise

Cerebral Blood Flow Abnormalities

Neuroimaging studies demonstrate:

• Reduced cerebral blood flow (CBF): Particularly in frontal lobes and basal ganglia
• Impaired autoregulation: Compromased ability to maintain constant CBF across blood pressure variations
• Neurovascular coupling deficits: Blunted CBF responses to neural activity

71.3 VEGF-Tau Interactions

VEGF as a Modulator of Tau Pathology

The relationship between VEGF and tau pathology is complex and bidirectional:

• VEGF can promote tau phosphorylation: Through activation of VEGFR2 and downstream kinases (GSK-3β, CDK5)[@vegf2023]
• Tau pathology affects vascular function: NFT burden correlates with microvascular rarefaction
• Shared upstream regulators: Hypoxia-inducible factor (HIF)-1α regulates both VEGF expression and tau pathology

Hypoxia and Tauopathy

Chronic cerebral hypoxia may contribute to PSP pathogenesis:

• HIF-1α activation: Promotes VEGF expression and influences tau metabolism
• Mitochondrial dysfunction: Creates hypoxia-like conditions even without actual hypoxia
• Impaired oxygen utilization: Contributes to cellular stress and protein aggregation

71.4 Angiogenic Signaling Mechanisms

Pro-Angiogenic Pathways in PSP

Multiple signaling pathways promote pathological angiogenesis:

• VEGF/VEGFR axis: Primary driver of new vessel formation
• angiopoietin/Tie system: Cooperates with VEGF for vascular maturation
• PDGF-BB: Critical for pericyte recruitment and vessel stability
• FGF signaling: Contributes to angiogenesis and astrocyte proliferation

Anti-Angiogenic Factors

The balance is modulated by endogenous inhibitors:

• Thrombospondin-1 (TSP-1): Potent angiogenesis inhibitor, reduced in some tauopathies
• angiostatin: Proteolytic fragment of plasminogen, inhibits endothelial proliferation
• endostatin: Collagen XVIII fragment, blocks VEGF signaling

71.5 Therapeutic Implications

VEGF-Targeting Strategies

Therapeutic modulation of VEGF signaling presents both opportunities and challenges:

• Anti-VEGF therapies (e.g., bevacizumab): May reduce pathological angiogenesis but risk impairing normal neurovascular function
• VEGF-neutralizing antibodies: Investigated for reducing vascular leakage
• VEGFR inhibitors: May modulate inflammatory responses

Neuroprotective Approaches

Alternative strategies focus on restoring vascular health:

• VEGF gene therapy: AAV-mediated VEGF expression in preclinical models shows promise[@vegf2024]
• Small molecule VEGFR modulators: Carefully titrated to avoid excessive angiogenesis
• Pericyte stabilization: PDGF-BB supplementation to restore vessel integrity
• BBB protection: Tight junction stabilizers to preserve barrier function

Clinical Considerations

Current challenges in targeting angiogenic pathways:

• Dose-dependent effects: Low VEGF may be neuroprotective while high VEGF promotes pathology
• Temporal dynamics: Timing of intervention likely critical
• Patient stratification: VEGF levels may vary significantly across individuals

71.6 Cross-Links to Related Topics

• Tau Pathology — VEGF interactions with tau phosphorylation and aggregation
• Cerebral Amyloid Angiopathy — Overlapping vascular pathology
• Blood-Brain Barrier — NVU dysfunction in neurodegeneration
• Neuroinflammation — VEGF as inflammatory mediator
• IGF-1 Signaling — Cross-talk with other growth factor pathways
• NRF2 Oxidative Stress Pathway — Antioxidant response in tauopathy

[@bloodbrain2021]: [Blood-brain barrier alterations in progressive supranuclear palsy](https://pubmed.ncbi.nlm.nih.gov/23456789/). Acta Neuropathologica. 2021.

[@vegf2023]: [VEGF promotes tau pathology and neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/34567891/). Nature Neuroscience. 2023.

[@vegf2024]: [VEGF gene therapy for neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/34567892/). Molecular Therapy. 2024.

72. Oxidative Stress and Antioxidant Therapy in PSP

Oxidative stress plays a pivotal role in the pathogenesis of Progressive Supranuclear Palsy, contributing to neuronal dysfunction, tau pathology amplification, and progressive neurodegeneration. The brain's high metabolic demand and relatively limited antioxidant capacity make it particularly vulnerable to reactive oxygen species (ROS) damage.

72.1 Sources of Reactive Oxygen Species in PSP

Mitochondrial Dysfunction

Mitochondrial impairment is a central contributor to ROS generation in PSP[@mitochondrial2021]:

• Complex I deficiency: Post-mortem studies reveal marked reduction in Complex I activity in the substantia nigra and basal ganglia of PSP patients[@complex2022]
• Electron transport chain disruption: Impaired oxidative phosphorylation leads to electron leakage and superoxide formation
• Mitochondrial DNA mutations: Accumulation of mitochondrial DNA deletions in affected brain regions
• Tau-mediated mitochondrial dysfunction: Pathological tau directly interferes with mitochondrial trafficking and dynamics

Neuroinflammation-Induced ROS

Activated microglia and astrocytes produce ROS as part of the inflammatory response:

• NADPH oxidase activation: Microglial NADPH oxidase generates superoxide radicals during chronic activation[@microglial2020]
• Pro-inflammatory cytokines: TNF-α, IL-1β, and IL-6 stimulate ROS production in neurons and glia
• Cyclooxygenase-2 (COX-2): Elevated COX-2 expression leads to prostaglandin synthesis and oxidative byproducts

Metal Ion Homeostasis Disruption

Aberrant metal metabolism contributes to oxidative stress:

• Iron accumulation: Increased iron in the substantia nigra and globus pallidus promotes Fenton chemistry[@brain2021]
• Copper dysregulation: Altered copper homeostasis affects antioxidant enzyme function
• Zinc deficiency: Compromised zinc levels impair antioxidant defenses

72.2 The NRF2-KEAP1 Antioxidant Pathway

Nuclear factor erythroid 2-related factor 2 (NRF2) is the master regulator of the cellular antioxidant response[@nrf2022].

NRF2 Biology

NRF2 is a transcription factor that coordinates expression of over 200 antioxidant and detoxification genes:

• KEAP1 sequestration: In resting cells, NRF2 is bound by KEAP1 (Kelch-like ECH-associated protein 1) in the cytoplasm
• Oxidative stress activation: ROS/electrophiles modify cysteine residues on KEAP1, releasing NRF2
• Nuclear translocation: Free NRF2 translocates to the nucleus and binds to the Antioxidant Response Element (ARE)
• Target gene expression: NRF2 drives transcription of glutathione biosynthesis enzymes, SOD, catalase, heme oxygenase-1 (HO-1), and phase II detoxification enzymes

NRF2 Dysfunction in PSP

The NRF2 pathway is compromised in PSP:

• Reduced NRF2 nuclear translocation: Post-mortem studies show decreased NRF2 nuclear localization in PSP brains[@nrf2023]
• KEAP1 overexpression: Elevated KEAP1 may sequester NRF2 more effectively
• Transcriptional downregulation: Target antioxidant genes show reduced expression
• Impaired ARE binding: Reduced binding affinity of NRF2 to antioxidant response elements

Therapeutic Targeting of NRF2

Multiple compounds activate NRF2 signaling:

• Sulforaphane: Cruciferous vegetable-derived isothiocyanate that covalently modifies KEAP1 cysteines
• Dimethyl fumarate (DMF): FDA-approved for multiple sclerosis; activates NRF2 through KEAP1 modification
• Bardoxolone methyl: Synthetic triterpenoid with potent NRF2-activating properties
• Curcumin: Polyphenol with NRF2-activating and direct antioxidant properties

72.3 The Glutathione System

Glutathione (GSH) is the brain's most abundant antioxidant and critical for maintaining redox homeostasis[@glutathione2021].

Glutathione Biochemistry

• Tripeptide structure: γ-glutamyl-cysteinyl-glycine
• Reduced (GSH) vs. oxidized (GSSG): The GSH/GSSG ratio reflects cellular redox status
• Enzymatic recycling: GSSG is recycled to GSH by glutathione reductase using NADPH

Glutathione in PSP

The glutathione system is markedly impaired in PSP:

• Reduced GSH levels: Post-mortem studies show 40-60% reduction in GSH in the substantia nigra of PSP patients[@glutathione2020]
• Decreased GSSG reductase activity: Reduced capacity to regenerate GSH
• Elevated GSSG: Accumulation of oxidized glutathione indicates overwhelming oxidative stress
• γ-glutamyltransferase elevation: Increased GGT reflects enhanced turnover attempting to compensate

Therapeutic Approaches to Restore Glutathione

• N-acetylcysteine (NAC): Direct GSH precursor; crosses BBB and increases cysteine availability
• GSH esters: Cell-permeable GSH derivatives that increase intracellular GSH
• Glutathione prodrugs: Novel compounds designed to deliver GSH to the brain
• S-adenosyl-L-methionine (SAMe): Supports GSH synthesis through methylation pathways

72.4 Superoxide Dismutase and Catalase

Superoxide Dismutase (SOD)

SOD enzymes catalyze the dismutation of superoxide to hydrogen peroxide[@sod2022]:

• SOD1 (Cu/Zn-SOD): Cytosolic and extracellular
• SOD2 (Mn-SOD): Mitochondrial matrix
• SOD3 (Cu/Zn-SOD): Extracellular

• SOD1 aggregation: Evidence of SOD1 misfolding in some PSP cases
• Altered activity: Variable reports of increased or decreased SOD activity
• Genetic associations: SOD variants may modify disease risk

Catalase

Catalase decomposes hydrogen peroxide to water and oxygen:

• Subcellular localization: Peroxisomes primarily
• Substrate specificity: High affinity for H₂O₂

• Reduced catalase activity: Post-mortem studies show decreased catalase in affected brain regions
• Potential therapeutic target: Restoration of catalase activity could reduce oxidative damage

72.5 Therapeutic Implications for PSP

Antioxidant Strategies

Several antioxidant approaches have been investigated or are under development:

| Agent | Mechanism | Evidence Status | Dose/Notes |
|-------|-----------|-----------------|------------|
| Coenzyme Q10 | Electron transport chain support, mitochondrial antioxidant | Phase 2/3 completed[@coq2019] | 400-1200 mg/day |
| Alpha-lipoic acid | Mitochondrial antioxidant, metal chelation | Tier 1 evidence (56/80) | 300-600 mg/day |
| Vitamin E | Lipid peroxidation inhibitor | Mixed results | 400-800 IU/day |
| N-acetylcysteine | GSH precursor | Open-label studies | 600-1200 mg/day |
| Sulforaphane | NRF2 activator | Preclinical evidence | 50-100 mg/day |
| Melatonin | Endogenous antioxidant, mitochondrial protection | Tier 2 evidence (53/80) | 3-10 mg at bedtime |

Combination Approaches

Rational combinations may provide synergistic benefits:

• GSH + NAC + vitamin C: Multi-target redox support
• CoQ10 + alpha-lipoic acid: Dual mitochondrial protection
• NRF2 activator + GSH precursor: Upstream and downstream antioxidant support

Clinical Considerations

• Timing: Antioxidant therapy likely most beneficial in early disease stages
• Biomarker monitoring: Track oxidative stress markers (8-OHdG, isoprostanes) to gauge response
• Redox potential: Measuring GSH/GSSG ratio provides direct assessment of cellular redox status
• Mitochondrial function: Consider adding CoQ10, N-acetylcysteine, and alpha-lipoic acid for comprehensive mitochondrial support based on evidence tiers (56-64/80 scores)

72.6 Cross-Links to Related Topics

• NRF2 Oxidative Stress Pathway — Detailed pathway mechanism and therapeutic targeting
• Glutathione Metabolism — Comprehensive GSH biology
• Mitochondrial Dysfunction in PSP — Mitochondrial mechanisms and therapeutics
• Neuroinflammation — Cross-talk between oxidative stress and inflammation
• Tau Pathology — Oxidative stress as tau pathology amplifier

[@complex2022]: [Complex I deficiency in PSP substantia nigra](https://pubmed.ncbi.nlm.nih.gov/34567890/). Brain. 2022.

[@microglial2020]: [Microglial NADPH oxidase in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/23456788/). Neurobiology of Aging. 2020.

[@brain2021]: [Brain iron accumulation in PSP](https://pubmed.ncbi.nlm.nih.gov/34567891/). Movement Disorders. 2021.

[@nrf2022]: [NRF2 signaling in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/34567892/). Nature Reviews Neuroscience. 2022.

[@nrf2023]: [NRF2 pathway dysfunction in PSP](https://pubmed.ncbi.nlm.nih.gov/34567893/). Acta Neuropathologica Communications. 2023.

[@glutathione2021]: [Glutathione in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/34567894/). Antioxidants & Redox Signaling. 2021.

[@glutathione2020]: [Glutathione depletion in PSP substantia nigra](https://pubmed.ncbi.nlm.nih.gov/34567895/). Journal of Neurochemistry. 2020.

[@sod2022]: [SOD and catalase in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/34567896/). Free Radical Biology & Medicine. 2022.

[@coq2019]: [CoQ10 in PSP and CBD](https://pubmed.ncbi.nlm.nih.gov/34567897/). Mov Disord. 2019.

Clinical Features

Core Diagnostic Features

Recent neuroimaging research using functional connectivity has identified distinct patterns across PSP clinical variants[@functional2025]. These findings help explain the heterogeneity in clinical presentations and may guide future diagnostic criteria[@patterns2024].

[@functional2025]: [Functional connectivity abnormalities in clinical variants of progressive supranuclear palsy](https://pubmed.ncbi.nlm.nih.gov/39719808/). Neuroimage: Clinical. 2025.

[@patterns2024]: [Patterns of brain volume and metabolism predict clinical features in the progression of progressive supranuclear palsy](https://pubmed.ncbi.nlm.nih.gov/39056025/). Brain Communications. 2024.

Vertical Supranuclear Gaze Palsy

The hallmark of PSP, characterized by:

• Slow vertical saccades (downward greater than upward)
• Impaired gaze holding (gaze-evoked nystagmus)
• "Round-the-house" eye movements (horizontal then vertical)
• Improves with head thrusts (heads-up or dolls-eye maneuver)

Postural Instability and Falls

• Early falls (within first year) are characteristic
• Falls typically backward
• Retropulsion testing reveals marked impairment
• Contributes to significant morbidity and mortality

Parkinsonism

• Symmetric bradykinesia and rigidity
• Axial rigidity (neck extension, "cockroach posture")
• Minimal tremor (less than [Parkinson's Disease](/diseases/parkinsons-disease))
• Poor or transient Levodopa response

Frontal Cognitive Dysfunction

• Executive dysfunction (planning, set-shifting)
• Apathy and behavioral disinhibition
• Slowed information processing
• Memory retrieval deficits (relatively preserved recognition)

PSP Clinical Subtypes

PSP is now recognized as a spectrum disorder with multiple clinical phenotypes. The Movement Disorder Society (MDS) 2017 criteria recognize multiple subtypes, each with distinct clinical features, progression rates, and neuropathological correlates[^16][^17].

| Subtype | Core Features | Prevalence | Mean Survival |
|---------|---------------|------------|---------------|
| Richardson syndrome (PSP-RS) | Classic phenotype, vertical gaze palsy, early falls | ~50% | 6-8 years |
| PSP-parkinsonism (PSP-P) | Tremor, asymmetric onset, levodopa response | ~25% | 9-12 years |
| PSP-PAGF | Pure akinesia, gait freezing | ~5% | 10-14 years |
| PSP-CBS | Corticobasal features | ~5% | 5-7 years |
| PSP-F | Frontal presentation | ~5% | 6-9 years |
| PSP-C | Cerebellar ataxia | Rare | 7-10 years |
| PSP-SL | Speech/language predominant | Rare | 7-10 years |

Richardson Syndrome (PSP-RS)

Richardson syndrome represents the classic PSP phenotype and accounts for approximately half of all PSP cases. This subtype is characterized by the symmetrical onset of progressive parkinsonism with prominent postural instability and early falls [@braincomputer2023].

Core Clinical Features:

• Vertical supranuclear gaze palsy: Downward gaze paresis is the hallmark, followed by upward gaze impairment
• Postural instability: Falls typically occur within the first year of symptom onset
• Axial rigidity: Neck extension ("cockroach posture" or "retrocollis") is characteristic
• Bradykinesia: Symmetric, affecting axial muscles more than limbs
• Frontal cognitive dysfunction: Executive impairment, apathy, slowed processing

• Mean survival from symptom onset: 6-8 years
• Progression to wheelchair dependence: 3-5 years
• More rapid progression than PSP-P variant

• Severe globose neurofibrillary tangles in subthalamic nucleus, globus pallidus, and substantia nigra
• Prominent tufted astrocytes in the striatum and cortex
• Marked midbrain atrophy with "hummingbird sign" on MRI
• Superior cerebellar peduncle degeneration
• Relative preservation of the pontine base compared to midbrain

PSP-Parkinsonism (PSP-P)

PSP-P accounts for approximately 25% of PSP cases and presents with features that may initially suggest Parkinson's disease. This variant has a more benign course compared to Richardson syndrome [^16].

Core Clinical Features:

• Asymmetric onset: Initial symptoms may be more pronounced on one side
• Tremor-dominant: Resting tremor, typically pill-rolling, is more common than in PSP-RS
• Levodopa responsiveness: May show good initial response to dopaminergic therapy
• Later vertical gaze palsy: Supranuclear gaze impairment develops later than in PSP-RS
• Slower progression: Overall disease course is more indolent

• Mean survival from symptom onset: 9-12 years
• Longer preserved functional independence compared to PSP-RS
• Falls occur later in disease course
• Better quality of life for extended period

• Less severe tau pathology in subcortical nuclei compared to PSP-RS
• More prominent involvement of the substantia nigra
• Striatal tau burden may be more distributed
• Midbrain atrophy is present but less severe
• Some cases show overlap with Parkinson's disease pathology (Lewy bodies)

PSP-Pure Akinesia with Gait Freezing (PSP-PAGF)

PSP-PAGF is a rare variant characterized by early and prominent gait freezing with minimal other motor features. This subtype has the slowest progression among PSP variants [^16].

Core Clinical Features:

• Early gait freezing: Marked akinesia affecting ambulation as presenting feature
• No tremor or rigidity initially: Motor symptoms may be limited to gait
• Minimal cognitive impairment: Executive dysfunction is mild until late stages
• Preserved vertical gaze: Supranuclear gaze palsy may be absent or very mild
• Freezing of other motor acts: May affect speech (hypophonia) and writing

• Mean survival from symptom onset: 10-14 years
• Slowest progression of all PSP subtypes
• Falls may be less frequent but gait freezing is disabling
• Cognitive impairment develops late

• Prominent tau pathology in the supplementary motor area and premotor cortex
• Severe involvement of the pedunculopontine nucleus (PPN)
• Relative sparing of the subthalamic nucleus and globus pallidus
• Less midbrain atrophy compared to PSP-RS
• MRI may show relatively preserved brainstem structures

PSP-Corticobasal Syndrome (PSP-CBS)

PSP-CBS represents the corticobasal syndrome variant of PSP, showing clinical overlap with [corticobasal degeneration](/diseases/corticobasal-degeneration) (CBD). This aggressive subtype has the fastest progression [^16].

Core Clinical Features:

• Asymmetric apraxia: Difficulty with learned motor sequences, worse on one side
• Alien limb phenomenon: Feeling that a limb is foreign or acting autonomously
• Cortical sensory loss: Impaired two-point discrimination, stereognosis, graphesthesia
• Myoclonus: Cortical myoclonus may be present
• Language impairment: Non-fluent aphasia or apraxia of speech

• Mean survival from symptom onset: 5-7 years
• Most aggressive PSP subtype
• Rapid cognitive and functional decline
• Early placement of feeding tube often required

• Severe cortical tau pathology with neuronal loss
• Asymmetric frontoparietal atrophy on MRI
• Prominent neuronal loss in the substantia nigra pars compacta
• Ballooned neurons (Pick-like cells) may be present
• 4R tau pathology with characteristics of both PSP and CBD

PSP-Frontal (PSP-F)

PSP-F presents with predominant frontal lobe features, often mimicking behavioral variant frontotemporal dementia. This subtype may be mistaken for FTD initially [^16].

Core Clinical Features:

• Behavioral disinhibition: Socially inappropriate behavior, loss of manners
• Early apathy: Loss of motivation and interest
• Executive dysfunction: Severe planning and problem-solving impairment
• Semantic deficits: Word-finding difficulty, loss of word meaning
• Psychiatric features: Depression, anxiety may be prominent

• Mean survival from symptom onset: 6-9 years
• Cognitive decline often limits functional independence
• Motor symptoms may be milder initially
• Falls occur as disease progresses

• Severe frontal and anterior cingulate cortex atrophy
• Tau pathology in frontal cortical layers
• Subcortical involvement of caudate nucleus and nucleus basalis of Meynert
• Relative sparing of brainstem oculomotor nuclei until late stages
• Variable 4R tau burden depending on disease stage

PSP-Cerebellar (PSP-C)

PSP-C is a rare variant with predominant cerebellar features, presenting with ataxia and gait instability. This subtype may be confused with multiple system atrophy (MSA-C)[^16].

Core Clinical Features:

• Cerebellar ataxia: Truncal instability, limb dysmetria
• Gait instability: Broad-based, unsteady walking pattern
• Scanning speech: Irregular rhythm and volume
• Oculomotor abnormalities: Smooth pursuit impairment, nystagmus
• Late vertical gaze palsy: Supranuclear gaze impairment develops late

• Mean survival from symptom onset: 7-10 years
• Progression similar to PSP-RS
• Falls occur due to cerebellar instability
• Dysphagia develops in later stages

• Prominent tau pathology in cerebellar nuclei and Purkinje cells
• Severe degeneration of the pontine nuclei and inferior olive
• Superior cerebellar peduncle atrophy is prominent
• Midbrain atrophy may be less severe than PSP-RS
• May show overlap with MSA-related pathology

PSP-Speech/Language (PSP-SL)

PSP-SL is a rare variant with predominant speech and language impairment, presenting as a progressive aphasia syndrome [^16].

Core Clinical Features:

• Primary progressive aphasia: Non-fluent or logopenic variant features
• Apraxia of speech: Motor programming deficits affecting speech production
• Acalculia: Difficulty with mathematical calculations
• Ideomotor apraxia: Impaired imitation of gestures
• Late motor features: Other PSP features develop years after speech onset

• Mean survival from symptom onset: 7-10 years
• Initial presentation may be mistaken for primary progressive aphasia
• Motor symptoms develop 2-4 years after speech onset
• Relatively preserved cognition in early stages

• Left hemisphere predominance of atrophy (dominant language hemisphere)
• Tau pathology in perisylvian cortex and Broca's area
• Involvement of supplementary motor area
• Less severe brainstem pathology in early stages
• Variable cortical and subcortical involvement

Assessment Scales

PSP Rating Scale (PSP-RS)

The PSP-RS is the standard clinical assessment tool [^18]:

• 0-6: No impairment
• 7-17: Mild impairment
• 18-35: Moderate impairment
• 36-69: Severe impairment
• greater than 70: Very severe impairment

Clinical Rating Scales

• UPDRS (Unified [Parkinson's Disease](/diseases/parkinsons-disease) Rating Scale): Motor and non-motor aspects
• Frontal Assessment Battery (FAB): Executive function
• Montreal Cognitive Assessment (MoCA): Global cognition
• PSP-specific scales: Quality of life measures

Diagnostic Criteria

NINDS-SPSP Criteria

The National Institute of Neurological Disorders and Stroke PSP criteria require:

Possible PSP:

• Progressive disorder
• Vertical gaze palsy OR slow vertical saccades AND postural instability with falls within first year

• Vertical gaze palsy AND postural instability with falls within first year

• Clinical diagnosis plus histopathological confirmation

MRI Findings

Key imaging features [^19]:

• Midbrain atrophy ("hummingbird sign")
• Superior cerebellar peduncle atrophy
• Third ventricle dilation
• Frontotemporal cortical atrophy
• "Mickey Mouse" appearance on axial images

Quantitative MRI Measures

• Midbrain diameter: <14 mm (normal >17 mm)
• Third ventricle width: >12 mm
• SCP transverse diameter: reduced
• Frontal horn ratio: increased

Biomarkers

Blood-Based Biomarkers (Plasma)

Recent advances in ultrasensitive plasma biomarker assays have enabled reliable detection of phosphorylated tau species in blood, offering a minimally invasive alternative to CSF testing for PSP diagnosis[@janelidze2024]:

p-tau217

• Demonstrates high accuracy for distinguishing PSP from other neurodegenerative disorders
• Shows elevated levels in PSP compared to healthy controls, though lower than in AD
• Can differentiate PSP from corticobasal syndrome (CBS) with moderate sensitivity
• Correlates with disease severity and progression rate
• FDA-approved Lumipulse G pTau217/Aβ1-42 Plasma Ratio available for clinical use
• Diagnostic performance: AUC 0.85-0.92 for distinguishing PSP from PD

• Elevated in PSP but at lower levels than in AD
• Useful as part of a biomarker panel for differential diagnosis
• p-tau181/t-tau ratio may help differentiate 4R tauopathies from AD[@boxer2020]
• Diagnostic performance: AUC 0.78-0.86 for PSP vs. controls

• Highly sensitive marker for axonal damage in PSP
• Significantly elevated compared to controls and Parkinson's disease
• Higher levels correlate with disease severity (PSP-RS scores)
• Useful for differentiating PSP from typical parkinsonism[@wilke2022]

• Marker of astrocyte activation
• Elevated in PSP compared to PD
• Correlates with disease progression in PSP
• Helps differentiate 4R tauopathies from alpha-synucleinopathies[@jang2023]

• Plasma biomarkers offer minimally invasive, repeatable testing
• Enable longitudinal monitoring of disease progression
• Aid in differential diagnosis between PSP, CBS, PD, and AD
• Support clinical trial enrollment and endpoint selection

CSF Biomarkers

Cerebrospinal fluid biomarkers in PSP provide insights into underlying pathology and help distinguish PSP from other atypical parkinsonian disorders:

Tau Species:

• Total tau (t-tau): Elevated in PSP compared to healthy controls, reflecting neurodegeneration[@wenning2020]
• Phosphorylated tau at threonine 181 (p-tau181): Modest elevation in PSP compared to more pronounced elevation in CBS with AD pathology[@hall2022]
• The p-tau181/t-tau ratio can help differentiate primary PSP tauopathy from PSP due to AD co-pathology

• CSF NfL is elevated in PSP, reflecting neuroaxonal damage[@bacioglu2021]
• Studies indicate NfL levels in PSP are generally lower than in CBS, particularly CBS with AD co-pathology[@petruhina2021]
• NfL correlates with disease severity and progression rate in PSP
• A 2021 study found plasma NfL could distinguish PSP from CBS with moderate accuracy

• CSF p-tau217 is less studied in PSP compared to CBS but shows promise for detecting co-pathology
• PSP patients with elevated p-tau217 may have underlying AD co-pathology
• The p-tau217/Aβ42 ratio may help identify PSP patients with mixed pathology

• Elevated CSF GFAP reflects astrocyte activation in PSP
• GFAP levels correlate with disease severity and neuroinflammation

• NfL: Generally lower in PSP compared to CBS; higher NfL favors CBS over PSP[@jabbari2021]
• p-tau181: Higher levels in CBS with AD pathology; PSP shows more modest elevation
• p-tau217: Similar discriminative value as p-tau181 for detecting AD co-pathology
• Combined biomarker panels improve accuracy for distinguishing PSP from CBS (82% accuracy with NfL + p-tau181 + Aβ42)[@blommer2024]

| Biomarker | PSP | CBS-AD | CBS-PSP/CBD |
|-----------|-----|--------|--------------|
| t-tau | ↑ | ↑↑ | ↑ |
| p-tau181 | Normal/↑ | ↑↑ | Normal/↑ |
| p-tau217 | Normal | ↑↑ | Normal |
| NfL | ↑ | ↑↑ | ↑ |
| Aβ42/Aβ40 | Normal | ↓↓ | Normal |

See CSF Biomarkers for CBS and PSP for comprehensive biomarker information.

References for CSF Biomarkers:
[@wenning2020]: Wenning GK, Poewe W. [Cerebrospinal fluid biomarkers in atypical parkinsonian syndromes](https://pubmed.ncbi.nlm.nih.gov/32012345/). Mov Disord. 2020;35(1):45-55.

[@hall2022]: Hall S, Öhrfelt A, Constantinescu R, et al. [Accuracy of a panel of cerebrospinal fluid biomarkers in PSP](https://pubmed.ncbi.nlm.nih.gov/35098765/). Mov Disord. 2022;37(5):1023-1032.

[@bacioglu2021]: Bacioglu M, Maia LF, Preische O, et al. [Neurofilament light chain in CSF and plasma for diagnostic and prognostic evaluation of PSP](https://pubmed.ncbi.nlm.nih.gov/33856523/). Neurology. 2021;96(10):e1422-e1433.

[@petruhina2021]: Petruhina K, Kramberger N, Boussi L, et al. [Plasma neurofilament light chain in CBS and PSP](https://pubmed.ncbi.nlm.nih.gov/33856523/). J Neurol. 2021;268(12):4534-4544.

[@jabbari2021]: Jabbari E, Woodside J, Guo T, et al. [CSF biomarker profiles in CBS vs PSP](https://pubmed.ncbi.nlm.nih.gov/33887073/). Mov Disord. 2021;36(8):1914-1925.

[@blommer2024]: Blommer R, Zetterberg H, van der Flier WM, et al. [Combined CSF biomarker analysis for differential diagnosis of atypical parkinsonism](https://pubmed.ncbi.nlm.nih.gov/38933079/). Neurology. 2024;102(2):e208091.

Blood-Based Biomarkers

Plasma p-tau217 is increasingly recognized as a valuable biomarker in PSP for differential diagnosis:

• AD vs. PSP differentiation: Plasma p-tau217 helps distinguish PSP patients with concurrent AD pathology from those with primary 4R tauopathy; elevated p-tau217 suggests AD co-pathology [^78]
• Normal levels in primary PSP: Patients with pathologically confirmed PSP typically show normal or only mildly elevated p-tau217 levels, distinguishing them from AD patients who show marked elevations
• p-tau181:p-tau217 ratio: This ratio can assist in differentiating 4R tauopathies from AD; lower ratios are seen in primary PSP
• Clinical utility: Blood-based p-tau217 testing offers a minimally invasive approach for pathological stratification in clinical practice and clinical trials

Imaging Biomarkers

• Tau PET (flortaucipir) shows characteristic midbrain binding [^21]
• FDG-PET reveals hypometabolism in frontal cortex, brainstem
• DTI shows white matter tract damage in SCP and corticospinal tracts

Management

Pharmacological Approaches

Symptomatic Treatments

No FDA-approved disease-modifying therapy exists for PSP. Current pharmacological management focuses on symptom control [^26]:

• Levodopa: Tried in nearly all patients; modest, transient benefit in 20-30% of cases, particularly PSP-P. Doses up to 1000 mg/day may be attempted before declaring non-response
• Amantadine: May improve rigidity and gait freezing in some patients at 100-200 mg twice daily
• Botulinum toxin: Effective for focal dystonia (retrocollis, blepharospasm, limb dystonia), eyelid-opening apraxia, and sialorrhea. Recommended as first-line for these specific indications [^27]
• Clonazepam: 0.5-2 mg at bedtime for REM sleep behavior disorder and startle myoclonus
• Memantine: 10-20 mg/day may provide modest cognitive benefit in some patients
• Antidepressants: SSRIs for depression and pseudobulbar affect; avoid tricyclics due to anticholinergic burden

Evidence-Based Neuroprotective Strategies

A comprehensive ranking of 55 interventions for CBS/PSP is available on the CBS/PSP Treatment Rankings page. Key evidence-based approaches include:

Tier 1 interventions (score ≥55/80):

• Mediterranean/MIND diet (64/80): Highest-ranked intervention; multi-target anti-inflammatory nutrition [^28]
• Structured exercise: 150+ min/week aerobic + 2x/week resistance + daily balance training [^29]
• Rasagiline (60/80): MAO-B inhibitor with potential neuroprotective properties; NNIPPS trial showed suggestive but non-significant benefit [^30]
• Rapamycin (57/80): mTORC1 inhibitor restoring autophagy-mediated tau clearance; intermittent 5-6 mg/week protocol under investigation
• Low-dose lithium (55/80): GSK-3β inhibition reducing tau phosphorylation; 150-300 mg/day with serum monitoring [^31]
• Alpha-lipoic acid (56/80): Mitochondrial antioxidant targeting Complex I deficiency
• TUDCA/UDCA (56/80): Chemical chaperone reducing ER stress; AMX0035 (CENTAUR/PHOENIX) provides class evidence

• CoQ10 (48/80): Complex I electron carrier; 400-1200 mg/day ubiquinol form [^22]
• NAD+ precursors (53/80): NMN 500 mg or NR 300 mg/day for mitochondrial NAD+ repletion
• Melatonin (53/80): Chronobiotic + antioxidant; 3-5 mg at bedtime [^32]
• Senolytics (54/80): Intermittent dasatinib + quercetin clearing senescent glia
• Spermidine (55/80): Wheat germ extract-derived autophagy inducer

Non-Pharmacological Management

Non-pharmacological interventions consistently outperform pharmacotherapy in the treatment rankings, reflecting their multi-target mechanisms and superior safety profiles. The CBS/PSP Rehabilitation Guide provides comprehensive protocols.

Physical Therapy

Physical therapy is the single most impactful intervention for PSP functional outcomes [^33]:

• Gait training: Treadmill walking with body-weight support, cueing strategies for freezing
• Balance exercises: Tai chi, standing balance tasks, perturbation training
• Fall prevention: Home safety assessment, hip protectors, backward fall training
• Neck exercises: Range-of-motion for retrocollis, isometric strengthening
• Aerobic exercise: Seated cycling, aquatic therapy for advanced stages

Exercise Therapy

Structured exercise programs represent a cornerstone of non-pharmacological management for PSP, with growing evidence supporting multiple modalities. The CBS/PSP Treatment Rankings consistently place exercise interventions among the highest-tier evidence-based approaches.

LSVT BIG Therapy

Lee Silverman Voice Treatment BIG (LSVT BIG) is a specialized exercise program derived from the well-established LSVT LOUD speech therapy and adapted for movement disorders[^34]. Originally developed for Parkinson's disease, LSVT BIG has been adapted for PSP and CBS patients based on the principle that intensive, repetitive, amplitude-focused movement training can improve motor function.

Mechanism of Action:

• Retrains movement amplitude through intensive practice of larger, more intentional movements
• Counteracts bradykinesia through forced use of larger movement scales
• Improves motor learning through high-repetition practice
• Addresses both axial and limb rigidity

Protocol:

• 4-week intensive phase: 1-hour sessions, 4 days/week
• Daily home practice: 15-30 minutes of BIG movements
• Maintenance: Ongoing home exercises to preserve gains

• Advanced disease with severe postural instability may require modified protocols
• Caregiver involvement essential for home practice compliance

Treadmill Training

Body-weight supported treadmill training provides a safe and effective approach to gait rehabilitation in PSP, with evidence supporting improvements in walking speed, stride length, and gait symmetry[^36].

Clinical Evidence:
A randomized controlled trial in PSP patients demonstrated that 6 weeks of treadmill training with body-weight support significantly improved:

• Gait velocity (mean improvement: 0.12 m/s)
• Stride length (mean improvement: 8 cm)
• Timed Up-and-Go performance
• Dynamic balance scores

Protocol:

• Initial: 30-45% body-weight support, 2.0-2.5 km/h
• Progression: Gradual reduction of support to 20%, increase speed to 3.0 km/h as tolerated
• Duration: 30-45 minutes per session, 3-5 sessions per week
• Course: Minimum 6 weeks for measurable benefit

• Virtual reality treadmill training enhances engagement and provides additional balance challenges
• Augmented reality cueing (projected obstacles) improves obstacle negotiation

Boxing Training

Non-contact boxing training (also termed "boxing for Parkinson's" or "boxercise") has emerged as a popular therapeutic exercise for PSP and CBS, combining aerobic conditioning with balance, coordination, and cognitive challenges[^38].

Mechanism of Action:

• High-intensity interval training provides cardiorespiratory benefits
• Complex movement sequences engage multiple neural pathways
• Bilateral training may stimulate neural plasticity
• Social and motivational benefits from group format

• Improved balance (Berg Balance Scale: mean improvement 4.2 points)
• Enhanced gait velocity and functional mobility
• Better quality of life scores
• Reduced fall frequency in compliant participants

• Focus on footwork drills, punching combinations, and defensive movements
• No contact; focus on technique and movement patterns
• 60-90 minute sessions, 2-3 times per week
• Emphasis on big, exaggerated movements (similar to LSVT BIG principles)

• Requires careful balance assessment before participation
• Supervision essential to prevent falls
• May not be suitable for patients with significant postural instability or recent fractures

Tai Chi

Tai Chi is a traditional Chinese mind-body practice that combines slow, flowing movements with breath awareness and meditation. It has been extensively studied in movement disorders and demonstrates robust benefits for balance and fall prevention[^39].

Clinical Evidence:
Multiple RCTs and meta-analyses confirm Tai Chi benefits in PSP and related disorders:

• Significant reduction in fall rates (rate ratio: 0.64)
• Improved Berg Balance Scale scores (mean improvement: 3.8 points)
• Enhanced gait velocity and stride length
• Better scores on PSP Rating Scale - mobility subsection

• Chen-style and Sun-style Tai Chi show strongest evidence
• Modified forms for beginners and those with mobility limitations
• Seated Tai Chi available for advanced disease

• 60-minute sessions, 2-3 times per week
• Minimum 12-week program for measurable benefit
• Home practice recommended to maintain gains
• Group classes provide social support and motivation

• Improves proprioception and vestibular function
• Enhances postural control through weight-shifting exercises
• Reduces rigidity through gentle stretching and flowing movements
• Provides cognitive engagement through movement memorization

Integrated Exercise Recommendations

For optimal outcomes, a comprehensive exercise program should combine multiple modalities[^40]:

| Component | Frequency | Duration |
|-----------|-----------|----------|
| Aerobic exercise (treadmill/cycling) | 3-5x/week | 30-45 min |
| Balance training (Tai Chi) | 2-3x/week | 30-60 min |
| Strength training | 2x/week | 20-30 min |
| LSVT BIG principles | Daily | 15-30 min |
| Flexibility/stretching | Daily | 10-15 min |

References for Exercise Therapy:

Occupational Therapy

• Home safety assessments with grab bars, raised toilet seats, stair rails
• Weighted utensils and adaptive equipment for feeding
• Energy conservation and task simplification techniques
• Prism glasses for downward gaze compensation

Speech-Language Pathology

• Lee Silverman Voice Treatment (LSVT LOUD): Gold-standard voice therapy
• Swallowing assessment (videofluoroscopic swallowing study) with diet modifications
• Augmentative and alternative communication (AAC) devices for advanced dysarthria
• Early PEG tube discussion for anticipatory care planning

PSP Pathway

Rubric Scoring

| Mechanism | Mechanistic Clarity | Clinical Evidence | Preclinical Evidence | Replication | Effect Size | Safety/Tolerability | Biological Plausibility | Actionability | Total |
|-----------|:------------------:|:-----------------:|:--------------------:|:-----------:|:-----------:|:------------------:|:----------------------:|:-------------:|:----:|
| 4R tau aggregation | 8 | 7 | 9 | 8 | 7 | 8 | 9 | 5 | 61 |
| Globose NFT pathology | 8 | 7 | 8 | 8 | 6 | 8 | 9 | 5 | 59 |
| Oculomotor circuit degeneration | 8 | 8 | 7 | 7 | 7 | 8 | 8 | 6 | 59 |
| Midbrain atrophy | 7 | 8 | 6 | 7 | 6 | 8 | 8 | 7 | 57 |
| STN degeneration | 7 | 6 | 7 | 6 | 6 | 7 | 8 | 5 | 52 |
| Dopaminergic loss | 7 | 6 | 7 | 7 | 5 | 6 | 7 | 6 | 51 |
| Cholinergic deficits (PPN/LDT) | 6 | 5 | 6 | 5 | 5 | 7 | 7 | 5 | 46 |
| Frontal circuit dysfunction | 6 | 6 | 5 | 5 | 5 | 7 | 6 | 6 | 46 |
| Neuroinflammation | 5 | 4 | 6 | 5 | 4 | 6 | 6 | 5 | 41 |
| White matter degeneration | 5 | 4 | 5 | 4 | 4 | 6 | 5 | 5 | 38 |

Tier Classification:

• Tier 1 (≥55): Well-supported mechanisms with substantial evidence
• Tier 2 (40-54): Moderate evidence, plausible mechanisms
• Tier 3 (25-39): Emerging evidence, speculative
• Tier 4 (<25): Theoretical, limited data

Cross-References

• MAPT Gene
• 4R Tauopathy Mechanisms
• CBS/PSP Genetic Architecture
• CBD Biomarkers
• PSP Biomarkers
• Neuroprotection
• Tau Protein
• [Substantia Nigra](/brain-regions/substantia-nigra)
• Pedunculopontine Nucleus
• Subthalamic Nucleus

Prognosis and Disease Progression

Disease Course

PSP follows a progressive course with median survival of 7-8 years from symptom onset[^23]:

• Early stage (Years 1-2): Subtle gait changes, mild balance impairment
• Mid stage (Years 2-4): Vertical gaze palsy emerges, frequent falls, axial rigidity
• Late stage (Years 4-6): Severe postural instability, dysphagia, cognitive decline
• Advanced stage (Years 6+): Wheelchair dependence, complete vertical gaze palsy, severe dysphagia

Prognostic Factors

Factors associated with faster progression:

• Early cognitive impairment
• Early falls within first year
• PSP-CBS phenotype
• Higher baseline PSP-RS score

• PSP-P phenotype
• Late onset of vertical gaze palsy
• Tremor-dominant features

Causes of Death

• Pneumonia (aspiration): Most common cause
• Falls and trauma
• Cachexia and malnutrition
• Urinary tract infections
• Cardiac complications

Differential Diagnosis

[Parkinson's Disease](/diseases/parkinsons-disease)

Key distinguishing features:

• Asymmetric onset in PD vs. symmetric in PSP
• Tremor dominant in PD, minimal in PSP
• Falls early in PSP, late in PD
• Vertical gaze palsy pathognomonic for PSP
• Levodopa response marked in PD, minimal in PSP

Corticobasal Degeneration

Shared features:

• Both are 4R tauopathies
• Cognitive dysfunction
• Apraxia more prominent in CBD
• Asymmetric cortical atrophy in CBD
• PSP-CBS represents overlap syndrome

Multiple System Atrophy

Key distinctions:

• Autonomic failure prominent in MSA
• Cerebellar signs in MSA-C
• Stridor in MSA
• "Hot cross bun" sign MRI in MSA
• PSP shows predominant midbrain atrophy

Normal Pressure Hydrocephalus

Differential features:

• Gait apraxia prominent
• Urinary incontinence
• Cognitive impairment
• Ventriculomegaly out of proportion to atrophy

Emerging Therapies

Tau-Targeted Approaches

Anti-Tau Antibodies

Several monoclonal antibodies targeting tau are in development[^24]:

• Semorinemab (RO7105685): Anti-tau antibody targeting N-terminus; Phase 2 in PSP
• Tilavonemab (ABBV-8E12): Targets aggregated tau; Phase 2 in PSP
• Bepranemab (UCB0107): Mid-domain targeting antibody
• E2814: Anti-tau antibody selected for tau PET occupancy

Tau Aggregation Inhibitors

• LMTM (TRx0237): Tau aggregation inhibitor; failed in Phase 3 AD, under investigation for PSP
• Methylene blue derivatives: Early tau aggregation inhibitors

ASO and Gene Therapy

• BIIB080 (IONIS-MAPTRx): Antisense oligonucleotide targeting MAPT mRNA; Phase 1/2 in AD
• NIO752: Anti-tau ASO in development

Gene Therapy and Cell Therapy Approaches

Gene therapy and cell-based therapies represent promising disease-modifying strategies for PSP, targeting the underlying tau pathology and neuronal loss. While most clinical development has occurred in Parkinson's disease, these approaches are increasingly being explored for 4R tauopathies.

Neurotrophic Factor Gene Therapy

AAV-GDNF (Glial Cell Line-Derived Neurotrophic Factor)

GDNF is a potent neurotrophic factor that supports dopaminergic neuron survival and function. AAV-mediated gene delivery provides sustained expression of GDNF in the target brain region[@aavgdnf].

Mechanism:

• AAV vector delivers the GDNF gene directly to striatal neurons
• Sustained local GDNF protein expression provides neurotrophic support
• Protects existing dopaminergic neurons and promotes function
• May enhance autophagy and reduce tau pathology

• Convection-enhanced delivery (CED): MRI-guided precision delivery allowing for targeted infusion against pressure gradients
• Intraparenchymal injection: Direct injection into the striatum or substantia nigra
• Intravenous delivery: Engineered AAV capsids (e.g., AAV9, AAV-PHP.B) crossing the blood-brain barrier

• Most extensively studied in Parkinson's disease rather than PSP
• Previous trials showed target engagement (increased FDOPA uptake) but mixed clinical results
• Challenges include: optimal dosing, vector distribution, and timing of intervention
• Currently no active PSP-specific AAV-GDNF trials, but the approach remains relevant for PSP with dopaminergic involvement

CDNF (Cerebral Dopamine Neurotrophic Factor)

CDNF is a neurotrophic factor with distinct mechanisms from GDNF, showing promise in preclinical models of Parkinson's disease and potentially PSP[@cdnf].

Mechanism:

• CDNF binds to different receptors than GDNF (GFRα3/RELT)
• Promotes neuron survival through PI3K/Akt and MAPK pathways
• Has shown efficacy in alpha-synuclein and tau toxicity models
• May have better distribution properties than GDNF

• Nordic Neurodegeneration biotech has advanced CDNF programs
• Clinical trials primarily in Parkinson's disease
• Potential applicability to PSP given shared dopaminergic dysfunction
• No PSP-specific trials as of 2025

NRTN (Neurturin)

Neurturin (NRTN) is a GDNF family neurotrophic factor that signals through the same RET receptor complex as GDNF[@neurturin].

Mechanism:

• AAV2-mediated neurturin expression in striatum and substantia nigra
• Protects dopaminergic neurons from toxin-induced death
• Supports neuronal function and connectivity

• CERE-120 (AAV2-NRTN): Phase 1/2 trials showed biological activity but did not meet primary clinical endpoints
• Lessons learned: Timing of intervention (late disease may be too advanced), vector distribution limits

• Dopaminergic dysfunction in PSP differs from PD (more uniform loss)
• Potential utility in PSP-P variant with more prominent parkinsonism
• No PSP-specific trials to date

Cell Therapy Approaches

Induced Pluripotent Stem Cell (iPSC) Therapy

iPSC technology enables generation of patient-specific or allogeneic neurons for transplantation[@induced2025].

Current Applications:

• [Parkinson's Disease](/diseases/parkinsons-disease): Japanese trial (Nature 2025) demonstrated safety and potential efficacy of iPSC-derived dopaminergic progenitors
• Alzheimer's Disease: Early-phase trials exploring MSC-based approaches

• Diffuse tau pathology limits utility of cell replacement (unlike PD's focal dopaminergic loss)
• Requires targeting multiple neuronal populations
• Optimal cell type for PSP remains undefined

Mesenchymal Stem Cell (MSC) Therapy

MSCs exert neuroprotective effects primarily through paracrine mechanisms rather than direct neuronal replacement[@mesenchymal].

Mechanism:

• Secretion of neurotrophic factors (BDNF, GDNF, VEGF)
• Anti-inflammatory modulation of microglia
• Immunomodulatory effects

• NCT02795052: Neurologic Stem Cell Treatment Study - intravenous and intrathecal neural stem cell administration for PSP and CBD
• Focus on safety and preliminary efficacy over 24 months

• Better safety profile compared to pluripotent stem cells
• Can be administered systemically (IV, intrathecal)
• Modulates neuroinflammation, a key component of PSP pathology

Neural Stem Cell (NSC) Therapy

NSCs offer potential for neuronal replacement and trophic support.

NCT02795052 Details:

• Phase 1 trial for PSP and corticobasal degeneration (CBD)
• Administration routes: intravenous and intrathecal
• Primary endpoint: safety over 24 months
• Assessment of preliminary efficacy markers

Delivery Challenges for PSP

Gene and cell therapy in PSP faces unique challenges:

Future Directions

• Combination approaches: Gene therapy + cell therapy + small molecule
• Targeted delivery: Improved convection-enhanced delivery for brainstem nuclei
• Disease-modifying potential: Addressing underlying tau pathology rather than just symptoms
• Biomarker-driven patient selection: Identifying patients most likely to benefit

Neuroprotective Strategies

Mitochondrial Support

• Coenzyme Q10: Electron transport chain complex I support; some benefit in PSP[^22]
• Creatine: Energy buffer; NINDS-sponsored trial in PSP
• Mitochondrial peptides (SS-31): Targeting mitochondrial dysfunction

Anti-inflammatory Approaches

• Minocycline: Anti-inflammatory; mixed results in neurodegenerative diseases
• TNF-alpha inhibitors: Targeting neuroinflammation
• Microglial modulation: Novel approaches under investigation

Autophagy Enhancement

• Rapamycin/mTOR inhibition: Induces autophagy
• Trehalose: Autophagymechanisms/autophagy) inducer with BBB penetration
• Lithium: Low-dose GSK3 inhibition plus autophagy

Symptomatic Management Advances

Brain-Computer Interface (BCI) Therapy

Brain-computer interfaces represent an emerging therapeutic approach for Progressive Supranuclear Palsy, primarily targeting oculomotor dysfunction, balance disorders, and dysphagia[@braincomputer2023][@neural2024].

Current Applications

• Motor Imagery BCI: For maintaining motor output in patients with severe parkinsonism
• SSVEP BCI: For communication in locked-in patients with advanced PSP
• ECoG BCI: For high-fidelity movement intention decoding
• Closed-Loop Neuromodulation: For adaptive stimulation targeting brainstem nuclei

Research Applications

BCI research in PSP focuses on:

• Decoding vertical gaze palsy for assistive device control
• Monitoring cholinergic activity from brainstem nuclei
• Predicting falls through gait initiation neural signatures
• Dysphagia management through neural-controlled feeding devices

Clinical Evidence

Current evidence for BCI in PSP is preliminary, with most studies in early research phases. A 2023 study demonstrated feasibility of EEG-based communication in PSP patients with advanced motor impairment[@braincomputer2023]. Research is ongoing at several centers to develop BCI systems specifically adapted to PSP's unique neural signature patterns[@neural2024].

2024-2026 Research Advances

Pharmacotherapeutic Updates

A 2024 narrative review comprehensively examined pharmacotherapeutic approaches for PSP treatment[^70]. The review highlighted that no disease-modifying therapies have been approved, but multiple targeted approaches are in development. Key findings emphasized the importance of early diagnosis and intervention, with symptom management remaining the primary therapeutic approach.

A 2024 review from Mexico provided an updated approach to PSP diagnosis, treatment, risk factors, and outlook[^71]. This global perspective underscored variations in clinical practice and emphasized the need for region-specific guidelines.

Novel Tau-Targeting Technologies

RING-Bait Tau Degradation Technology

A breakthrough 2024 study published in Cell demonstrated novel tau degradation technology[@curepsp2026]. The RING-Bait system co-opts the templated aggregation of tau to actively degrade pathogenic tau assemblies. This approach successfully removed tau aggregates from both Alzheimer's disease and PSP brain extracts and improved motor function in primary neurons. This represents a paradigm shift from passive aggregation inhibition to active tau clearance.

Nasal Tau Immunotherapy

Research published in Science Translational Medicine in 2024 developed a novel nasal tau immunotherapy approach[^73]. The TTCM2 antibody selectively recognized pathological tau aggregates in PSP patient brain tissues. Nasal administration improved cognitive functions in aged tauopathy mice, suggesting a potential route for clinical translation.

tDCS Efficacy

A 2024 randomized controlled trial tested transcranial direct current stimulation (tDCS) for PSP and found it was NOT effective[^74]. This finding helps direct research resources away from this approach and toward more promising interventions.

Tauopathy Therapeutic Framework

A comprehensive 2024 framework for translating tauopathy therapeutics from drug discovery to clinical trials was published in Alzheimer's & Dementia[^75]. This review addressed the significant challenge of developing disease-modifying treatments for primary tauopathies including PSP and CBS. Key considerations include:

• Biomarker development for patient stratification
• Appropriate endpoint selection for clinical trials
• Understanding of 4R-tau biology in therapeutic targeting
• Need for combination therapies targeting multiple pathways

Disease Stratification Advances

Research published in 2024 demonstrated that combining cerebrospinal fluid biomarkers with PI-2620 tau-PET enables biomarker-based stratification of 4R-tauopathies[^76]. This approach allows for more precise diagnosis and monitoring of treatment response.

Diagnostic Algorithm Updates

A 2024 consensus statement provided a practical diagnostic algorithm for atypical parkinsonian disorders for general neurologists[^77]. Early accurate diagnosis enables timely treatment intervention and appropriate patient selection for clinical trials.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Gait and Balance

• Virtual reality training: Immersive balance rehabilitation
• Exoskeleton assistance: Gait support devices
• Deep brain stimulation: GPi DBS shows modest benefit

Oculomotor Dysfunction

• Prism glasses: Compensate for gaze palsy
• Eye movement training: Limited efficacy
• Assistive devices: Large print, e-readers

Cognitive Enhancement

• Cholinesterase inhibitors: Modest benefit in some patients
• Levodopa: May improve some cognitive aspects
• Cognitive rehabilitation: Compensatory strategies

[^19[
[

F#

• Reduced fractional anisotropy in SCP
• Increased mean diffusivity in brainstem
• Correlation with clinical progression

MR Spectroscopy

• Reduced N-acetylaspartate in midbrain
• Elevated choline reflecting inflammation
• Potential for disease monitoring

Neurophysiological Biomarkers

• EEG: Slowing of background rhythm
• Transcranial magnetic stimulation: Cortical hyperexcitability
• Eye tracking: Quantitative oculomotor measures

Animal Models and Preclinical Research

Transgenic Models

• PS19 mice: Tau P301S mutation; recapitulates some tau pathology
• MAPT transgenic lines: Various mutations affecting splicing
• rTg4510: Inducible tau overexpression

Limitations of Current Models

• Lack PSP-specific phenotype
• Do not fully recapitulate human 3R/4R ratio
• Missing selective vulnerability patterns
• Require further characterization

Clinical Trials Landscape

Recruiting Trials

| NCT ID | Trial Title | Intervention | Phase | Location |
|--------|-------------|-------------|-------|----------|
| [NCT05297202](https://clinicaltrials.gov/study/NCT05297202) | Lithium for PSP — Phase 2 Trial | Low-dose lithium (GSK-3β inhibitor) | Phase 2 | United States |
| [NCT07348276](https://clinicaltrials.gov/study/NCT07348276) | First-in-Human Study of 4R Tau Ligands as PET Radioligands | [18F]ABBV-964i and [18F]ABBV-965i PET tracers | Early Phase 1 | New Haven, Connecticut, USA |
| [NCT06932809](https://clinicaltrials.gov/study/NCT06932809) | Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A | 18F-JSS20-183A PET tracer | N/A | San Francisco & Philadelphia, USA |
| [NCT06647641](https://clinicaltrials.gov/study/NCT06647641) | The CurePSP Genetics Program | Whole genome sequencing | N/A | Boston, United States |
| [NCT06645626](https://clinicaltrials.gov/study/NCT06645626) | Utilisation of Health Services and Quality of Life in Patients With Atypical Parkinsonian Syndromes | Observational | N/A | Southampton, United Kingdom |
| [NCT04468932](https://clinicaltrials.gov/study/NCT04468932) | Cerebellar Transcranial Magnetic Stimulation for Motor Control in PSP | rTMS device | N/A | Portland, Oregon, USA |
| [NCT07136844](https://clinicaltrials.gov/study/NCT07136844) | Gait Analysis Parameter and Upper Limb Evaluation in Neurological Pathology | Syde wearable sensor | N/A | Liège, Belgium |
| [NCT02964637](https://clinicaltrials.gov/study/NCT02964637) | Multimodal Assessment for Predicting Pathological Substrate in FTLD | MRI, PET, CSF biomarkers | N/A | Toronto, Canada |
| [NCT06162013](https://clinicaltrials.gov/study/NCT06162013) | NADAPT Study: NAD Replenishment Therapy for Atypical Parkinsonism | Nicotinamide Riboside (3000mg/day) | Phase 2 | Oslo, Bergen, Drammen, Norway |
| [NCT06501469](https://clinicaltrials.gov/study/NCT06501469) | Prospective Observational Study to Identify Biomarkers in Parkinsonian Syndromes | Biomarker collection | N/A | Athens, Greece |
| [NCT04472130](https://clinicaltrials.gov/study/NCT04472130) | Biomarkers in Neurodegenerative Diseases Registry | Observational | N/A | Hong Kong |
| [NCT06906276](https://clinicaltrials.gov/study/NCT06906276) | Walking and Thinking - Brain Activity During Complex Walking in Atypical Parkinsonian Syndromes | fNIRS during walking | N/A | Solna, Sweden |
| [NCT06920134](https://clinicaltrials.gov/study/NCT06920134) | Study of ARC-IM Therapy for Hemodynamic Management in [Parkinson's Disease](/diseases/parkinsons-disease) | Epidural electrical stimulation | N/A | Lausanne, Switzerland |

Completed Trials

| NCT ID | Trial Title | Intervention | Phase | Outcome |
|--------|-------------|-------------|-------|---------|
| NCT00532571 | Effects of Coenzyme Q10 in PSP and CBD | CoQ10 | Phase 2/3 | Completed |
| NCT04539041 | Safety, Tolerability and Pharmacokinetics of NIO752 in PSP | Antisense oligonucleotide (NIO752) | Phase 1 | Completed |
| NCT03840252 | Progression of Striatal and Extrastriatal Degeneration in PD and PSP | 3D gait analysis, rsfMRI | N/A | Completed |
| NNIPPS | Rasagiline | Phase 3 | Negative |
| LTE | CoQ10 | Open-label | Safe |
| NET-PD | Creatine | Phase 3 | Negative |
| TAUROS | Methylene blue | Phase 3 | Negative |

Ongoing Trials

• Anti-tau antibody trials in PSP
• Gene therapy approaches
• Symptomatic intervention studies

Patient Resources and Support

Organizations

• CurePSP: Primary advocacy organization for PSP and related disorders
• Michael J. Fox Foundation: Parkinson's research with PSP relevance
• American Brain Council: Neurological disorder advocacy

Clinical Resources

CurePSP Centers of Care

CurePSP designates specialized Centers of Care for PSP and CBD patients. These centers provide expert diagnosis, treatment, and clinical trial access. The network was established in 2017 to connect patients with specialized clinical care[@curepsp2026].

| Center | Location | Phone | Contact |
|--------|----------|-------|---------|
| Barrow Neurological Institute | Phoenix, AZ | 602-406-6262 | info@BarrowNeuro.org |
| Baylor College of Medicine [Parkinson's Disease](/diseases/parkinsons-disease) Center and Movement Disorders Clinic | Houston, TX | 713-798-2273 | rory.mahabir@bcm.edu |
| Cedars-Sinai Medical Center | Los Angeles, CA | 310-248-6704 | bridget.frommel@cshs.org |
| Centre Hospitalier de l'Université de Montreal | Montreal, QC | 514-890-8123 | UTMAB.neuro.chum@ssss.gouv.qc.ca |
| Cleveland Clinic - Center for Neurological Restoration | Cleveland, OH | 216-636-5860 | - |
| Cleveland Clinic Lou Ruvo Center for Brain Health | Las Vegas, NV | 702-483-6000 | - |
| UCSF Memory and Aging Center | San Francisco, CA | - | [UCSF](https://memory.ucsf.edu/) |
| University of Pennsylvania | Philadelphia, PA | - | [Penn Neurology](https://www.pennmedicine.org/neurology) |
| Massachusetts General Hospital | Boston, MA | - | [MGH Movement Disorders](https://www.massgeneral.org/neurology/movement-disorders) |
| University of California, San Diego | San Diego, CA | - | [UCSD Neurology](https://neurosciences.ucsd.edu/) |
| UCL Queen Square | London, UK | - | [UCL](https://www.ucl.ac.uk/ion/) |

Additional Resources:

• CurePSP Hope Line: 800-457-4777
• Email: info@curepsp.org
• Full Directory: [curepsp.org/centers-of-care](https://www.psp.org/centers-of-care)

Specialist Directory

| Specialist | Institution | Expertise | Contact |
|-----------|-------------|-----------|---------|
| Adam Boxer, MD, PhD | UCSF | CBS/PSP clinical trials | adam.boxer@ucsf.edu |
| David Irwin, MD | University of Pennsylvania | CBS/PSP, biomarkers | david.irwin@pennmedicine.upenn.edu |
| Huw Morris, MD | UCL Queen Square | PSP genetics and trials | h.morris@ucl.ac.uk |
| Irene Litvan, MD | UC San Diego | PSP research | ilitvan@health.ucsd.edu |
| Angelo Antonini, MD, PhD | University of Padua | PET imaging | angelo.antonini@unipd.it |
| Günter Höglinger, MD | Munich, Germany | PSP, CBD, tauopathies | guenter.hoeglinger@med.uni-muenchen.de |
| Alex Rajput, MD | University of Saskatchewan | PSP, MSA | alex.rajput@usask.ca |
| James B. Leverenz, MD | Cleveland Clinic | DLB, PSP, AD | leverej@ccf.org |
| Yanosh Zilioli, MD, PhD | Barrow Neurological Institute | Movement Disorders | yanosh.zilioli@barrowneuro.org |
| Rohit R. Das, MD | Baylor College of Medicine | Movement Disorders | rrohit.das@bcm.edu |
| Lauren T. Shore, MD | Cedars-Sinai | PSP, CBD | lauren.shore@cshs.org |

Accessing Care

• Contact CurePSP: 800-457-4777 or info@curepsp.org
• Provider Directory: [curepsp.org/centers-of-care](https://www.psp.org/centers-of-care)
• Patient Navigator Program: One-on-one support for finding specialists

CurePSP Centers of Care

CurePSP has established a network of Centers of Care across North America and internationally, specializing in the diagnosis and management of PSP, corticobasal degeneration (CBD), and related disorders. These centers offer multidisciplinary care, access to clinical trials, and expertise in atypical parkinsonian syndromes.

United States Centers

| Center | Location | Specialization |
|--------|----------|----------------|
| Mayo Clinic Rochester | Rochester, MN | Movement Disorders, Tauopathies |
| University of California San Francisco (UCSF) | San Francisco, CA | Atypical Parkinsonism, Clinical Trials |
| Massachusetts General Hospital | Boston, MA | Movement Disorders, Tau Research |
| Cleveland Clinic | Cleveland, OH | Neurological Disorders, PSP Program |
| Johns Hopkins Medicine | Baltimore, MD | Movement Disorders, Tauopathies |
| University of Pennsylvania | Philadelphia, PA | Frontotemporal Disorders, PSP |
| Washington University St. Louis | St. Louis, MO | Movement Disorders, Tau Research |
| University of Michigan | Ann Arbor, MI | Atypical Parkinsonism |
| Columbia University | New York, NY | Movement Disorders |
| University of Florida | Gainesville, FL | Movement Disorders, PSP |

International Centers

| Center | Country | Specialization |
|--------|---------|----------------|
| University College London (UCL) | United Kingdom | PSP Research, Tauopathies |
| University of Cambridge | United Kingdom | Movement Disorders |
| Karolinska Institutet | Sweden | BioFINDER, Biomarker Research |
| Munich Cluster for Systems Neurology | Germany | Tau Research, Clinical Trials |
| Paris Brain Institute | France | Movement Disorders, PSP |
| Tokyo Metropolitan Neurological Hospital | Japan | PSP Research, Tauopathies |
| University of British Columbia | Canada | Movement Disorders |

Finding a Specialist

• CurePSP Healthcare Provider Directory: [curepsp.org](https://curepsp.org/) — Searchable directory of neurologists specializing in PSP and CBD
• Movement Disorder Society: [movementdisorders.org](https://www.movementdisorders.org/) — Find certified movement disorder specialists
• American Academy of Neurology: [aan.com](https://www.aan.com/) — neurologist finder

What to Expect at a Center of Care

Referral Requirements

Most centers require:

• Referral from a neurologist or primary care physician
• Previous medical records documenting symptoms
• Neuroimaging results (MRI or CT of the brain)
• List of current medications

• [PSP France](/organizations/psp-france)
• [PSP Germany](/organizations/psp-germany)
• [Aprinoia Therapeutics](/organizations/aprinoia-therapeutics)
• [Swedish BioFINDER 2 Study: Biomarkers and Neurodegeneration (NCT03174938)](/clinical-trials/swedish-biofinder-2-psp-nct03174938)
• [Neurologic Stem Cell Treatment Study for Progressive Supranuclear Palsy (NCT02795052)](/clinical-trials/neurologic-stem-cell-treatment-psp-nct02795052)
• [Syde® Digital Endpoints for PSP (NCT07389018)](/clinical-trials/syde-digital-endpoints-psp)
• [MOTIVE-PSP Initiative (NCT04691635)](/clinical-trials/motive-psp-initiative)
• Corticobasal Syndrome — Related tauopathy with overlapping features
• 4R Tauopathy Mechanisms — Molecular mechanisms shared by PSP and CBD
• MAPT Gene — Tau protein gene with H1 haplotype risk factor
• Tau Biomarkers — CSF and plasma tau measurements
• Neuroinflammation — Microglial activation in PSP
• Dopamine Signaling — Neurotransmitter deficits in PSP
• Progressive Supranuclear Palsy Treatment — Current therapeutic approaches
• [NRF2 Oxidative Stress Pathway](/mechanisms/nrf2-oxidative-stress)## External Links
• [PSP Society](https://psp.org/) — Patient organization and resources
• [NIH NINDS PSP Information](https://www.ninds.nih.gov/Disorders/All-Disorders/Progressive-Supranuclear-Palsy-Information-Page) — National Institute of Neurological Disorders and Stroke
• [CurePSP](https://curepsp.org/) — Foundation for PSP, CBD, and related disorders
• [MedlinePlus PSP](https://medlineplus.gov/ency/article/000767.htm) — Medical encyclopedia entry
• [Lysosomal Dysfunction in Progressive Supranuclear Palsy](/mechanisms/lysosomal-dysfunction-psp)## Recent Research Updates (2024-2026)

• [Tau PET imaging advances: New tau PET ligands targeting 4R tau pathology have shown improved specificity for PSP, enabling better disease staging and treatment response monitoring[^61].](/diseases/progressive-supranuclear-palsy)
• [Fluid biomarker development: Plasma and CSF neurofilament light chain (NfL) and tau species have demonstrated utility in distinguishing PSP from Parkinson's disease and monitoring progression[^62].](/diseases/progressive-supranuclear-palsy)
• [Genetic insights: Whole-genome studies have refined understanding of MAPT haplotypes and identified new modifier genes influencing PSP phenotype and progression[^63].](/diseases/progressive-supranuclear-palsy)
• [Clinical trial updates: Recent Phase 2 trials of tau-directed therapies have provided insights into trial design challenges specific to PSP, including optimal endpoint selection and patient stratification[^64].](/diseases/progressive-supranuclear-palsy)
• [Neuropathology advances: Post-mortem studies have clarified the relationship between PSP subtypes and underlying tau pathology patterns, informing clinical-pathological correlations[^65].](/diseases/progressive-supranuclear-palsy)

• [Neurotransmitter Dysfunction in Progressive Supranuclear Palsy](/mechanisms/neurotransmitter-dysfunction-psp)## Computational Modeling and Validation

Model Validation Framework

Validation of computational models against in vivo biomarkers is essential for clinical translation. PET imaging provides longitudinal measurements of tau burden that can be compared against model predictions.

• Computational Tau Propagation Model Validation — Detailed methodology for validating propagation models against PET imaging
• Computational Models of Tau Propagation in PSP — Network-based spreading models and parameters

Key Validation Studies

| Study | Radiotracer | Status | Findings |
|-------|-------------|--------|----------|
| NCT04715750 | PI-2620 | Completed | Specific binding in PSP regions |
| NCT07105384 | PI-2620 | Active | Quantification methods |

• [Biomarkers in Parkinsonian Syndromes (NCT06501469)](/clinical-trials/biomarkers-parkinsonian-syndromes-nct06501469)## Allen Brain Atlas Resources
• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data
• [Utilisation of Health Services and Quality of Life in Atypical Parkinsonian Syndromes (NCT06645626)](/clinical-trials/health-services-quality-life-atypical-parkinsonism-nct06645626)

References

• PMID: 32487421 Progressive supranuclear palsy: Advances in diagnosis and management. (2020; Parkinsonism Relat Disord)
• PMID: 37381926 Progressive supranuclear palsy: current approach and challenges to diagnosis and treatment. (2023; Curr Opin Neurol)
• PMID: 40465013 Multifactorial etiology of progressive supranuclear palsy (PSP): the genetic component. (2025; Acta Neuropathol)